QuidelOrtho Corporation

QDEL

US2197981051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 15:15:01 13/09/2024 BST			5-day change	1st Jan Change
45.40 ^USD	+1.34%		+4.33%	-38.49%

12:12pm	RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	MT
09-11	QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer	CI

Presentation Operator MessageOperator (Operator)Welcome to the QuidelOrtho Second Quarter 2024...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about QuidelOrtho Corporation

RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	11:12am	MT
QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer	09-11	CI
Transcript : QuidelOrtho Corporation Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 09:40 AM	09-10
QuidelOrtho Shares Rise After Craig-Hallum Upgrade	09-05	MT
Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40	09-05	MT
Transcript : QuidelOrtho Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:00 AM	09-05
QuidelOrtho Says FDA Approved Syphilis Assay on Disease-Testing Platform	08-29	MT
Tranche Update on QuidelOrtho Corporation's Equity Buyback Plan announced on August 17, 2022.	08-01	CI
Transcript : QuidelOrtho Corporation, Q2 2024 Earnings Call, Jul 31, 2024	07-31
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q2 Revenue $637M, vs. Street Est of $614.9M	07-31	MT
QuidelOrtho Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-31	CI
QuidelOrtho Corporation(NasdaqGS:QDEL) added to S&P 600 Health Care	07-25	CI
QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400 Health Care	07-25	CI
QuidelOrtho Corporation(NasdaqGS:QDEL) added to S&P 600	07-25	CI
QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400	07-25	CI
Avantor to Replace Quidel in S&P MidCap 400; Quidel to Replace Hibbett in S&P SmallCap 600	07-24	MT
RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	06-24	MT
QuidelOrtho Seeks Inorganic Options	06-05	CI
Transcript : QuidelOrtho Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 01:20 PM	06-05
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ	05-15	CI
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	05-14	RE
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	05-14	MT
Jana Partners Acquires Stake in QuidelOrtho	05-14	MT
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	05-14	RE
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	05-09	MT

QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.

Employees

7,100

Sector

Advanced Medical Equipment & Technology

Calendar

29/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company